- Home
- RPTX vs IVA Comparison
RPTX vs IVA Comparison
Compare RPTX & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- IVA
- Stock Information
- Founded
- RPTX 2016
- IVA 2011
- Country
- RPTX Canada
- IVA France
- Employees
- RPTX N/A
- IVA N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- RPTX Health Care
- IVA Health Care
- Exchange
- RPTX Nasdaq
- IVA Nasdaq
- Market Cap
- RPTX 63.9M
- IVA 359.6M
- IPO Year
- RPTX 2020
- IVA 2020
- Fundamental
- Price
- RPTX $1.41
- IVA $3.01
- Analyst Decision
- RPTX Strong Buy
- IVA Strong Buy
- Analyst Count
- RPTX 3
- IVA 4
- Target Price
- RPTX $4.50
- IVA $10.50
- AVG Volume (30 Days)
- RPTX 81.7K
- IVA 18.3K
- Earning Date
- RPTX 08-05-2025
- IVA 03-26-2025
- Dividend Yield
- RPTX N/A
- IVA N/A
- EPS Growth
- RPTX N/A
- IVA N/A
- EPS
- RPTX N/A
- IVA N/A
- Revenue
- RPTX $1,073,000.00
- IVA $14,591,573.00
- Revenue This Year
- RPTX N/A
- IVA $15.38
- Revenue Next Year
- RPTX N/A
- IVA $24.22
- P/E Ratio
- RPTX N/A
- IVA N/A
- Revenue Growth
- RPTX N/A
- IVA N/A
- 52 Week Low
- RPTX $0.89
- IVA $1.53
- 52 Week High
- RPTX $4.29
- IVA $4.05
- Technical
- Relative Strength Index (RSI)
- RPTX 56.42
- IVA 40.84
- Support Level
- RPTX $1.40
- IVA $3.00
- Resistance Level
- RPTX $1.45
- IVA $3.23
- Average True Range (ATR)
- RPTX 0.05
- IVA 0.21
- MACD
- RPTX -0.00
- IVA -0.04
- Stochastic Oscillator
- RPTX 63.64
- IVA 5.08
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.